1138-P: Continuous Glucose Monitor (CGM)–Based Glycemic Variability Is Associated with Beta-Cell Function in Youth at Risk for Type 2 Diabetes

Introduction Δ30 is the difference from 0 to 30 minutes. Log-transformation was performed for skewed distributions. Linear regression was used to evaluate the association between oDI outcomes and GV measures, adjusted for BMI Z-score. Results: Of 39 youth enrolled, 33 (55% F; 30% Black, 58% White, 12% multiracial; mean ± SD 14.9±1.8y; BMI 36.8±6.6 kg/m2; HbA1c 5.6±3.2%; FG 84.8±8.2 mg/dL; 2hG 116.2±28.9 mg/dL) had evaluable CGM data. MAGE and MODD were inversely associated with I-oDI (p=0.04, p=0.02) and C-oDI (p=0.009, p=0.016). CV (p=0.047) and SD (p=0.03) were inversely associated with C-oDI but not associated with I-oDI. Conclusion: Based on its demonstrated association with β-cell function, CGM-based GV offers a novel approach to evaluating T2D risk in youth with overweight/obesity and other risk factors. Disclosure C. Harrison: None. A. Rodriguez Gonzalez: None. B. Hewitt: None. S.A. Arslanian: Consultant; AstraZeneca, Eli Lilly and Company, Nestlé Health Science, Avoro Capital Advisor LLC. Research Support; Eli Lilly and Company, Novo Nordisk. Advisory Panel; Novo Nordisk. M. Vajravelu: None. Funding Endocrine Fellows Foundation; Tanner Scholar Advancing Equity Award